RxDoctor Payments Data

Clifford Jeng, MD

Foot and Ankle Surgery · Baltimore, MDNPI 1851339550

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $44,938 of the $74,215 with a category attached, or 60.6%. Smith+Nephew accounts for 60.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $19,474 and has fallen 98.3% since, to $337 in 2025. Among foot and ankle surgery clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$74,215in general payments, 2019–2025

Across 94 payments — averaging $789.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$45K
  • Stryker$19K
  • Integra Lifesciences Corporation$6K
  • Ascension Orthopedics, Inc.$3K
  • Supreme Orthopedic Systems, LLC$755
  • Paragon 28, Inc.$285
  • plus $446 from 7 others
$82,799in research payments, 2019–2025

Across 9 payments — averaging $9199.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Paragon 28, Inc.$58K
  • Arthrex$25K

What the payments were for

  • Royalty or licence$19,09126%
  • Consulting fees$44,93861%
  • Speaking & faculty fees$5,2507%
  • Travel & lodging$2,7214%
  • Food & beverage$1,6322%
  • Education$5841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,215 in reported general payments places this provider in the 95th percentile of 182 foot and ankle surgery providers in Maryland.

See all foot and ankle surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$131,484
Medicare patients
438
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cefadroxil31$120
Ondansetron Hcl21$89
Oxycodone Hcl14$71

Paid to pharmacies, not to this prescriber.

Other foot and ankle surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →